Overview

A class action lawsuit has been filed against Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) and certain of the Company’s current senior executive officers alleging violations of the federal securities laws.  The Company’s common stock trades on the NASDAQ under the symbol “TMCI.”

The Treace Medical class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Treace Medical securities between May 8, 2023, and May 7, 2024, both dates inclusive (the “Class Period”).

Treace Medical is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities.  It has patented the Lapiplasty 3D Bunion Correction System (the “Lapiplasty”), a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint.  The Company sells these products to physicians, surgeons, hospitals, and ambulatory surgery centers in the United States.  A key business metric the Company reports is the average selling price generated from each Lapiplasty kit sold to surgeons.

The Treace Medical class action lawsuit alleges that Defendants, throughout the Class Period, made materially false and/or misleading statements, as well as failed to disclose adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty; (2) as a result, Treace Medical’s revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

As a result of Defendants’ wrongful acts, omission, and the precipitous decline in the market value of the Company’s securities, Plaintiff and other Class members have suffered significant losses and damages.

*          *          *

If you purchased or otherwise acquired Treace Medical securities between May 8, 2023, and May 7, 2024, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Treace Medical class action lawsuit is June 10, 2025.